Document:

Wells Fargo Foothill Consent

 Exhibit 4.1 
 

 
 VIA FACSIMILE: (617) 523-1697 
 May 5, 2006 
 Douglas Tindle, Vice President 
 Wells Fargo Foothill, Inc. 
 One Boston Place, 18th Floor 
 Boston, Massachusetts 02103 
  

	 	RE:	ThermaClime, Inc. Loan and Security Agreement dated April 13, 2001, as amended (the “Loan Agreement”) 

 Dear Doug: 
 LSB Industries,
Inc. (“LSB”) will loan ThermaClime, Inc. (“ThermaClime”) $6.4 million (the “LSB Loan”), so that ThermaClime can redeem all of its outstanding 10 3/4% Senior Notes due 2007 (the “Senior Notes”). The LSB Loan will be evidenced by a term promissory note, in the form attached hereto, bearing interest at a rate of
10 3/4% that will mature on December 1, 2009. The LSB Loan is permitted under the terms of the Loan
Agreement since indebtedness owing by any Borrower (ThermaClime) to any Guarantor (LSB) is deemed permitted indebtedness under the Loan Agreement. It is expected that redemption will occur in late May or June, 2006. $6.3 million of principal remains
outstanding under the Senior Notes. 
 Under the terms of the Loan Agreement, except under certain conditions which are not
applicable in this case, ThermaClime may not repurchase any Senor Notes. Accordingly, ThermaClime, as administrative borrower, hereby requests that Wells Fargo Foothill, as the arranger and administrative agent for the Lenders party to the Loan
Agreement (“Wells Fargo Foothill”), consent to the redemption of the Senior Notes by ThermaClime, by signing below where indicated. 
 Please feel free to contact me with any questions. Thank you. 
  

	
	Sincerely,
	
	 /s/ David M. Shear

	 David M. Shear

	 General Counsel

 16 South Pennsylvania Avenue • Oklahoma City, Oklahoma 73107 • Phone: (405)
235-4546 • Facsimile: (405) 236-1209 

 Douglas Tindle, Vice President 
 Wells Fargo Foothill, Inc. 
 May 5, 2006 
 Page 2

 CONSENT 
 Notwithstanding the terms of the Loan and Security Agreement, Wells Fargo Foothill hereby consents to the redemption of the Senior Notes by ThermaClime. 
  

			
	WELLS FARGO FOOTHILL
		
	By:	 	 /s/ Douglas Tindle

		 	Douglas Tindle, Vice PresidentConsent of Orix Capital Markets, LLC

 Exhibit 4.2 
 CONSENT 
 THIS CONSENT dated as of May 12, 2006 is made in connection with that
certain Loan Agreement (the “Senior Credit Agreement”) dated as of September 15, 2004 among THERMACLIME, INC., an Oklahoma corporation (“ThermaClime”), each subsidiary of ThermaClime listed as a
“Borrower” on the signature pages of the Senior Credit Agreement a Cherokee Nitrogen Holdings, Inc. (together with ThermaClime and such subsidiaries, each a “Borrower” and collectively, jointly and severally, the
“Borrowers”), ORIX CAPITAL MARKETS, LLC, a Delaware limited liability company (“ORIX”), as agent for the Lenders such capacity, together with any successor or replacement Agent, the “Agent”),
and the Lenders that are now or hereafter at any time parties to the Senior Credit Agreement. Capitalized terms used herein and not otherwise defined herein shall have the meaning ascribed thereto in the Senior Credit Agreement. 
 WHEREAS, ThermaClime proposes to obtain a loan (the “Loan”) from its parent company LSB Industries, Inc.
(“Parent”) in the principal amount of $6,400,000, as evidenced that certain Term Promissory Note (the “Note”), dated May 12, 2006, and to use the proceeds of such loan (the “Loan Proceeds”)
solely to repurchase for the face amount thereof including accrued interest thereon, outstanding ThermaClime Notes which are not held by Parent; and 
 WHEREAS, the Borrowers, Parent and Agent are parties to that certain Subordination Agreement (the “Subordination Agreement”) dated as of May 12, 2006, pursuant to which, alia, the
obligations of the Borrowers in respect of the Loan were subordinated to the Senior Obligations in accordance with the terms set forth in the Subordination Agreement; and 
 WHEREAS, the proposed use of the Loan Proceeds would violate the covenants of the Senior Credit Agreement and therefor requires the consent of the Requisite Lenders. 
 NOW, THEREFORE, Agent and the undersigned Lenders hereby agree as follows: 
 Subject to the Loan constituting Permitted Indebtedness under the Senior Credit Agreement, each of Agent and the undersigned Lenders (i) consents to
the interest rate of 10.75% per annum provided for in the Note, (ii) consents to the utilization of the Loan Proceeds by ThermaClime solely to repurchase for the face amount thereof, including accrued interest thereon, outstanding
ThermaClime Notes which are not held by Parent; provided, however, that such repurchase must be completed within ninety (90) days after the date of the Subordination Agreement, and (iii) waives the covenants in the Senior
Credit Agreement to the extent such covenants would be violated solely due to the interest rate under the Note as provided in clause (i) above and the utilization of the Loan Proceeds as provided in clause (ii) above. Nothing contained
herein shall be construed as a waiver by Agent or Lenders of any covenant or provisions of the Senior Credit Agreement (other than as expressly set forth herein) or the other Agreements, or any other contract or instrument between Agent and/or
Lenders and any Borrower, and the failure of Agent or Lenders at any time or times hereafter to require strict performance by any Borrower of any provision thereof shall not waive, affect or diminish any right of Agent or Lenders to
thereafter demand strict compliance therewith. Each of Agent and Lenders hereby reserves all rights granted under the Senior Credit Agreement, the Other Agreements and any other contract or instrument between any Borrower and Agent and/or Lenders.

 IN WITNESS WHEREOF, the Agent and the undersigned Lenders have executed this Consent as of the date first
above written. 
  

			
	AGENT:
	
	 ORIX CAPITAL MARKETS, LLC,
 as
Agent for the Lenders

		
	By:	 	 /s/ Christopher L. Smith

	 Name:
	 	 Christopher L. Smith

	 Title:
	 	 Authorized Representative

	
	LENDERS:
	
	 ORIX FINANCE CORP.,
 as a
Lender

		
	By:	 	 /s/ Christopher L. Smith

	 Name:
	 	 Christopher L. Smith

	 Title:
	 	 Authorized Representative

	
	 ORPHEUS FUNDING LLC
 By its Manager
Guggenheim Investment Management, LLC

		
	By:	 	 /s/ Bill Hagner

	 Name:
	 	 Bill Hagner

	 Title:
	 	 Director and Counsel

		
	By:	 	 /s/ David Hahm

	 Name:
	 	 David Hahm

	 Title:
	 	 Director and Counsel

	
	KC CLO I LIMITED
		
	By:	 	  
	 Name:
	 	
	 Title:
	 	

			
	CALIFORNIA PUBLIC EMPLOYEES’ RETIREMENT SYSTEM
	
	 By: Highland Capital Management, L.P.,
 as Authorized Representatives of the Board

		
	By:	 	  
	 Name:
	 	
	 Title:First Amendment to Transitional Supply Agreement

 Exhibit 10.1 
 FIRST AMENDMENT TO 
 TRANSITIONAL SUPPLY AGREEMENT 
 This First Amendment to Transitional Supply Agreement (“Amendment”) is entered into effective as of July 1, 2006 between Warner Chilcott
Company, Inc., a Company organized under the laws of the Commonwealth of Puerto Rico (“Supplier”), and Pfizer Inc., a Delaware corporation (“Pfizer”). 
 RECITALS 
  

	A.	Supplier and Pfizer are the Parties to the Transitional Supply Agreement dated May 31, 2004 (the “Original Agreement”); and 

  

	B.	Supplier and Pfizer now wish to amend the Original Agreement in accordance with the terms of this Amendment. 

 AGREEMENT 
 NOW, THEREFORE, Supplier and Pfizer agree as
follows: 
 1. The following definitions are added to Section 1.1 of the Original Agreement: 
 “Dissolution Yield Losses” shall have the meaning set forth in Section 2.7. 
 “Standard Costs” for each Product shall have the meaning set forth in Schedule C. 
 2. The following sentence is added to the end of Section 2.1 of the Original Agreement: 
 Further, Supplier will be the exclusive supplier of Dilantin Products to Pfizer and its Affiliates during the Term of this Agreement. 
 3. The phrase “Zithromax® tablets in blisters,” in the second line of Section 2.2 of the Original Agreement is deleted in its entirety. 
 4. Section 2.7(a) of the Original Agreement is deleted in its entirety and replaced with the following: 
 2.7 Yield. (a) Supplier will use its commercially reasonable efforts to obtain maximum yield of the Products from the
Materials provided by Pfizer in connection with the Manufacture of such Products as provided hereunder. Supplier agrees that the yield loss rate for each such Product shall not exceed the rate set forth on Schedule I for such Product. In the
event the yield loss for all produced batches of a Product over any given twelve (12) month period during 

 the Term exceeds the yield loss rate for that Product as set forth on Schedule I, then Supplier
will reimburse Pfizer for Pfizer’s full standard costs (including, transportation fees, insurance fees, etc.) for those Materials that were supplied by Pfizer for use in Manufacturing Product lost in excess of the rate set forth on
Schedule I. For purposes of calculating the yield loss rate under this Section 2.7, yield losses resulting from dissolution failure in connection with the Manufacture by Supplier of Dilantin will be excluded unless such failures resulted
from Supplier’s failure to follow applicable standard operating procedures (except as provided in Schedule K) or Supplier’s negligence (“Dissolution Yield Losses”). In the event there are Dissolution Yield Losses, Pfizer
will be responsible for the costs of all Materials used in connection with the Manufacture of the lost Product. In addition, Pfizer shall pay Supplier its Standard Costs for the Manufacture of the lost Product based on the actual yield of the
Manufactured lot, not the theoretical yield. 
 5. The parenthetical in the third line of Section 3.2 is deleted in its entirety and
replaced with the following: 
 (other than Zyrtec® and certain orders for Dilantin as specified in Pfizer’s Firm Orders, which will be in bulk form) 
 6. Section 4.1 of the Original Agreement is deleted in its entirety and replaced with the following: 
         4.1 Pricing. Pfizer shall pay Supplier’s Standard Costs for the Manufacture of the Products
plus, in the case of Dilantin, an additional manufacturing charge and a packaging charge, all as set forth in Schedule C to the Agreement. 
 7. The phrase “by check delivered to Supplier’s address as designated in such invoice or” in the third and fourth lines of Section 4.2 of the Original Agreement is deleted in its entirety. 
 8. The last sentence of Section 5.4 of the Original Agreement is deleted in its entirety and replaced with the following: 
 Supplier shall provide sufficient office space in the Fajardo Plant for one Pfizer representative for the purpose of facilitating Pfizer’s
performance of such consultation. 
 9. The reference to Section 8.3 in Section 7.3 of the Original Agreement is an error and
should refer instead to Section 8.1. 
 10. The last sentence of Section 8.1 of the Original Agreement is deleted in its entirety.

  

 Page 2 of 10 

 11. The products Zithromax® and Benadryl® in all forms are deleted from Schedule A of the Original Agreement, and Dilantin 100 mg bulk capsules is added. 
 12. The Specifications for all Zithromax® and Benadryl® products in Schedule B of the Original Agreement are deleted. 
 13.
Schedule C to the Original Agreement is deleted in its entirety and replaced with the new Schedule C attached to this Amendment as Attachment 1. 
 14. The following additional row is added to the end of the table in Schedule D to the Original Agreement: 
  

			
	Dilantin 100mg bulk capsules	 	18 months

 and the rows for Zithromax® and Benadryl® and the footnote in Schedule D to the Original Agreement are deleted in their entirety. 
 15. Schedule G to the Original Agreement is deleted in its entirety and replaced with the new Schedule G attached to this Amendment as
Attachment 2. 
 16. The Yield Loss limits set forth on Schedule I of the Original Agreement related to Benadryl® and Zithromax products are deleted. 
 17. In consideration of the mutual promises and covenants set forth herein, Pfizer and Supplier will enter into an Assignment and Bill of Sale in
substantially the form attached to this Amendment as Attachment 3, transferring to Supplier, ownership of (a) the Gral & Drum Inverter (Asset nos. 2000-24-006101651 and 2000-24-006101656) and (b) the Fowler capper (Asset
no. 2004-02-000820788), and all related spare parts thereto (collectively, the “Equipment”) set forth in such Assignment and Bill of Sale. The Parties agree that the Equipment was part of the Retained Equipment under the Original Agreement
and that, such Equipment is deleted from Schedule H to the Original Agreement. 
 18. All capitalized terms used in this Amendment and not
otherwise defined in this Amendment have the meanings assigned them in the Original Agreement. 
 19. Except as expressly stated in this
Amendment, the Original Agreement remains unchanged and in full force and effect. Deletions of Sections of the Original Agreement shall not impact the numbering of the Sections. 
  

 Page 3 of 10 

 IN WITNESS WHEREOF, Pfizer and Supplier have executed this Amendment through their duly authorized
representatives, effective as of the date first set forth above. 
  

			
	PFIZER INC.
		
	By:	 	 /S/ KAREN KATEN

	Name:	 	Karen Katen
	Title:	 	Vice Chairman
	
	WARNER CHILCOTT COMPANY, INC.
		
	By:	 	 /S/ ANTHONY BRUNO

	Name:	 	Anthony Bruno
	Title:	 	Executive Vice President

  

 Page 4 of 10 

 Attachment 1 
 Revised Schedule C 
  
 Attached

  

 Page 5 of 10 

 SCHEDULE C 
 STANDARD COSTS 
 1. Standard Cost 
 a. The standard costs set forth in this Schedule C (the “Standard Costs”) shall include the cost of Manufacturing the Product, including
the cost of raw materials, labor, and other direct and identifiable variable costs and applicable costs for equipment pools, plant operations and plant support services, but shall not include profit or operating margin. The costs for plant
operations and plant support services will include utilities, maintenance, engineering, safety, human resources, finance, plant management and other similar activities. The plant operations and support services costs will be allocated in accordance
with GAAP and on a basis consistent with the calculation of the Standard Costs set forth in Section 1.c below. 
 Standard Costs may be
adjusted annually by Supplier to reflect changes in Supplier’s costs in Manufacturing the Products under this Agreement. The annual adjustments will be effective as of January 1 of each year and will be communicated in writing (the
“Adjustment Notice”) to Pfizer not later than November 15 of the preceding year. Supplier will base its calculations of the proposed new Standard Costs on a twelve-month forecast provided by Pfizer to Supplier no later than
August 15th of the prior year (such projections being the “Pfizer Twelve-Month Forecast”). If Pfizer
disagrees with Supplier’s proposed new Standard Costs, Pfizer may, within 15 days of delivery of the Adjustment Notice, deliver a notice (the “Disagreement Notice”) to Supplier disagreeing with such adjustments and setting forth
Pfizer’s calculation of such amount. If Pfizer and Supplier do not reach agreement with respect to the calculation of the proposed new Standard Costs (specifically, that the projected Standard Costs properly and accurately reflects the fully
loaded cost for the Product) within 15 days of Supplier’s receipt of the Disagreement Notice, then the parties shall promptly engage a mutually acceptable independent accountant to review the disputed items or amounts set forth in the
Disagreement Notice for the purpose of calculating the new Standard Costs. Such independent accountant shall deliver a report as promptly as practicable setting forth such calculation and such report shall be final and binding on the parties. The
cost of such review and report shall be borne equally by the parties. If Supplier does not provide an Adjustment Notice for a Product as provided in this paragraph, then the Standard Costs for such product will remain unchanged for that calendar
year. 
 b. In addition to the rights afforded in the paragraph above, no more than once each calendar year Pfizer may, upon prior written
notice and during normal business hours, review Supplier’s records relating to any changes in Supplier’s costs relating to such Product supporting an adjustment in the standard costs for Manufacturing such Product in accordance with this
Schedule C. All such information reviewed by Pfizer will be considered Confidential Information of Supplier. 
  

 Page 6 of 10 

 c. Set forth in Exhibit A hereto is the Standard Cost for each SKU of Products effective as of the date
hereof: 
 If, the portion of the aggregate purchase price of the actual volumes of Dilantin Products purchased from July 1, 2006 through
December 31, 2006 (including any Dissolution Yield Losses for which Supplier was indemnified pursuant to Section 2.7) that is attributable to the fixed overhead component of Standard Costs (i) is less than the amount of the Adjusted
Fixed Overhead set forth in Exhibit A hereto, or in any new Standard Costs accepted by the parties pursuant to Section 1.a of this Schedule C (the “Adjusted Fixed Overhead”), Supplier shall issue Pfizer an invoice for the amount of
such shortfall, and (ii) is more than the Adjusted Fixed Overhead, Supplier shall issue Pfizer a credit equal to the amount of such excess. 
 If, at
the end of each calendar year other than 2006, the portion of the aggregate purchase price of actual volumes of Dilantin Products purchased (including any Dissolution Yield Losses for which Supplier was indemnified pursuant to Section 2.7) that
is attributable to the fixed overhead component of Standard Costs (i) is less than Supplier’s calculation of Adjusted Fixed Overhead based the volumes projected in the applicable Pfizer Twelve-Month Forecast, Supplier shall issue Pfizer an
invoice for the amount of such shortfall, and (ii) is more than Supplier’s calculation of Adjusted Fixed Overhead based the on volumes projected in the applicable Pfizer Twelve-Month Forecast, Supplier shall issue Pfizer a credit for the
amount of such excess. 
 2. Special Terms Relating to Dilantin Products (all SKUs) 
 a. In addition to the Standard Costs for Dilantin set forth in this Schedule C, Pfizer will pay to Supplier the following fees for the services
provided by Supplier under this Agreement: 
  

							
	 Period
	  	Manufacturing Fee	  	Packaging Fee
	 7/1/06-6/30/07
	  	$	4,500,000.00	  	$	1,500,000.00
	 7/1/07-6/30/08
	  	$	4,500,000.00	  	$	2,000,000.00
	 7/1/08-6/30/09
	  	$	5,000,000.00	  	$	2,000,000.00
	 *7/1/09-6/30/10
	  	$	6,500,000.00	  	$	1,000,000.00
	 *7/1/10-6/30/11
	  	$	7,000,000.00	  	$	1,000,000.00

	*	Subject to Pfizer’s exercise of its right to renew the Term applicable to Dilantin Products for these periods as set forth in Schedule G of this Agreement.

 b. The amounts set forth in Paragraph 2(a), above, will be payable in two (2) equal installments of fifty percent
(50%) of the amount due, on or before the June 30 immediately preceding the commencement of the relevant period, and the second on or before the December 31 that falls during the relevant period. In the event of an early termination
of the Term applicable to Dilantin for any reason other than termination by Supplier under Section 8.2, Pfizer will be entitled to 
  

 Page 7 of 10 

 receive a pro rata refund of the Manufacturing Fee and Packaging Fee actually paid by Pfizer for the then-current period
calculated by multiplying (a) the Manufacturing Fee and Packaging Fee actually paid by Pfizer for the then-current period by (b) a fraction, (i) the numerator of which is the number of complete months remaining in the then-current
period after the date of termination of the Term applicable to Dilantin and (ii) the denominator of which is six (6). 
 c. Pfizer may
also at any time request that Supplier cease providing packaging services for Dilantin upon ninety (90) days’ prior written notice. Commencing the effective date of such termination, Supplier will no longer be required to provide packaging
services to Pfizer, and Pfizer will no longer be required to pay the Packaging Fee set forth above. Further, Pfizer will be entitled to receive a pro rata refund of the Packaging Fee actually paid by Pfizer for the then-current period calculated by
multiplying (a) the Packaging Fee actually paid by Pfizer for the then-current period by (b) a fraction, (i) the numerator of which is the number of complete months remaining in the then-current period after the date of termination of
packaging services and (ii) the denominator of which is six (6). 
  

 Page 8 of 10 

 Attachment 2 
 Revised Schedule G 
 Attached 
  

 Page 9 of 10 

 SCHEDULE G 
 PRODUCT TERM 
  

			
	 PRODUCT
	 	 TERM ENDS

	 Dilantin (all SKUs)
	 	June 30, 2009*
		
	 Zyrtec Chewable (all SKUs)
	 	July 31, 2006

	*	Provided that the Term applicable to Dilantin has not been previously terminated pursuant to Sections 8.2 or 8.3, Pfizer may, at its option, extend the Term applicable to Dilantin
for up to two (2) additional one (1) year periods (each an “Extension Term”) by providing written notice to Supplier no later than (a) September 30, 2008 for the first Extension Term; and (b) September 30,
2009 for the second Extension Term. 

  

 Page 10 of 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]